Jason Choe

Jason Choe

Auto-generated profile, based on publicly available information

Jason Choe

Department of Pharmacy New York Presbyterian Hospital New York City New York USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
NLNicholas W. Lange
Nicholas W. Lange
DSDavid M. Salerno
David M. Salerno
DJDouglas L. Jennings
Douglas L. Jennings
JCJason Choe
Jason Choe
JHJessica Hedvat
Jessica Hedvat
MPMarcus R. Pereira
Marcus R. Pereira

30 December 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
JHJessica Hedvat
Jessica Hedvat
NLNicholas W. Lange
Nicholas W. Lange
DSDavid M. Salerno
David M. Salerno
EDErsilia M. DeFilippis
Ersilia M. DeFilippis
DKDanielle Kovac
Danielle Kovac
MPMarcus R. Pereira
Marcus R. Pereira
Treatment outcomes associated with the use of novel COVID-19 therapeutics in solid organ transplant recipients (SOTR) are not well described in the literature. The objective of this analysis was to characterize 30-day hospitalization and other key secondary endpoints experienced by outpatient SOTR with mild–moderate COVID-19 treated with nirmatrelvir/ritonavir (NR), sotrovimab, or no SARS-CoV-2 specific treatment. This IRB-approved, retrospective study included 154 SOTR with a documented positive SARS-CoV-2 infection between December 16, 2021 and January 19, 2022 (a predominant Omicron BA.1 period in New York City). Patients who received NR (N = 28) or sotrovimab (N = 51) experienced a lower rate of 30-day hospitalization or death as compared to those who received no specific treatment (N = 75) (p = .009). A total of three deaths occurred, all among patients who initially received no specific treatment prior to hospitalization. These results suggest a role for SARS-CoV-2 specific agents in the treatment of SOTR with COVID-19, and that there does not appear to be any difference in effectiveness when comparing NR versus sotrovimab.

15 January 2022 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
JHJessica Hedvat
Jessica Hedvat
DSDavid M. Salerno
David M. Salerno
DKDanielle Kovac
Danielle Kovac
JSJenna L. Scheffert
Jenna L. Scheffert
HCHeather Corbo
Heather Corbo
NLNicholas W. Lange
Nicholas W. Lange

8 August 2024 in Clinical Transplantation
Verified
Journal Article
Closed access
XHXinyi Huang
Xinyi Huang
DSDavid Salerno
David Salerno
DKDanielle Kovac
Danielle Kovac
JSJenna Scheffert
Jenna Scheffert
JHJessica Hedvat
Jessica Hedvat
DJDouglas L. Jennings
Douglas L. Jennings

18 November 2024 in Clinical Transplantation
Verified
Journal Article
Closed access
XHXinyi Huang
Xinyi Huang
MYMelana Yuzefpolskaya
Melana Yuzefpolskaya
PCPaolo C. Colombo
Paolo C. Colombo
JCJason Choe
Jason Choe
TSTara Shertel
Tara Shertel
DJDouglas L. Jennings
Douglas L. Jennings

7 April 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
PDF file
HLH.S. Lumish
H.S. Lumish
PKP.J. Kennel
P.J. Kennel
DCD. Concha
D. Concha
ACA. Chung
A. Chung
DOD. Oren
D. Oren
GSG. Sayer
G. Sayer
Purpose New-onset post-transplantation diabetes mellitus (DM) is common among heart transplant (HT) recipients and has been shown to be associated with higher rates of renal dysfunction and death or re-transplantation. There are limited data to describe the use of novel anti-diabetic therapies in this population. We aimed to describe the prevalence of newly diagnosed DM and DM treatment patterns in HT patients at a single high-volume transplant center. Methods Patients undergoing HT between 1/2010-12/2017 were retrospectively reviewed. Patients undergoing repeat HT were excluded from the analysis. New-onset DM was defined by HbA1c >= 6.5% or initiation of anti-diabetic therapy. Data were collected from the electronic medical record. Results 280 transplant patients were identified with a median follow-up of 5.1 (IQR 2.6-8.1) years. 95 (33.9%) had pre-transplant DM. Of the 185 remaining patients, 45 (24.3%) developed post-HT DM with a median time to diagnosis of 109 (IQR 20-439) days. Median age of those with new-onset DM was 54 (IQR 47-61) years and 37.8% were female. Risk of PTDM was 18.2% at 1 year, 20.0% at 2 years, 23.8% at 5 years, and 33.1% at 10 years (Fig 1a). Hypertension was independently associated with post-HT DM (p = 0.014, Fig 1b). Among all patients with DM in the post-transplant period (N=140), 10 (7.1%) were started on a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and 17 (12.1%) were treated with a glucagon-like peptide-1 receptor agonist (GLP-1 RA). Adverse events with SGLT2i included polyuria in 2 patients, and adverse events with GLP-1 RA included gastrointestinal disturbance in 2 patients, palpitations in 1 patient, and discontinuation for unknown reasons in 1 patient. Conclusion DM is a common co-morbidity among HT recipients, with a high rate of pre-existing DM and post-HT DM. Utilization of the newest anti-diabetic agents with known cardiovascular benefits remains low in this cohort.